RxDoctor Payments Data

Michelle Schmerge

Adult Health · Charlotte, NCNPI 1366629057

Payments from drug & device makers

$3,663in general payments, 2019–2025

Across 23 payments — averaging $159.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AstraZeneca$99
  • Novo Nordisk$62
  • Lilly USA, LLC$32
  • Pfizer$32
  • Exact Sciences$30
  • plus $33 from 2 others

What the payments were for

  • Speaking & faculty fees$3,37592%
  • Food & beverage$2888%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,663 in reported general payments places this provider in the 85th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$109,299
Medicare patients
168
Services billed
1,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept13$103,969
MounjaroTirzepatide58$70,502
EliquisApixaban68$57,736
OzempicSemaglutide53$54,648
JardianceEmpagliflozin40$43,709
FarxigaDapagliflozin Propanediol22$19,306
XareltoRivaroxaban25$16,666
JanuviaSitagliptin Phosphate11$14,782
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,159
Spiriva HandihalerTiotropium Bromide16$9,275
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$8,747
EntrestoSacubitril/Valsartan12$7,924
NamzaricMemantine Hcl/Donepezil Hcl13$7,702
MyrbetriqMirabegron14$6,610
Allopurinol18$2,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$32$70,50258 claims
PfizerEliquis$32$57,73668 claims
Novo NordiskOzempic$62$54,64853 claims
AstraZenecaFarxiga$99$19,30622 claims
Johnson & JohnsonXarelto$3,375$16,66625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 adult health providers in North Carolina.

Other adult health in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →